Effect of IL-6R blockade on plasma lipids and clinical outcomes among hospitalized patients with COVID-19 infection
Journal of Lipid Research · 2024
DOI: 10.1016/j.jlr.2024.100568 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of Lipid Research, 2024. Verfasst von Kusha Mohammadi und 5 weiteren Autor:innen. Beteiligte Einrichtung: Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA. Hauptthemen laut MEDLINE: Receptors, Interleukin-6, Antibodies, Monoclonal, Humanized, COVID-19, Lipids. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Regeneron Pharmaceuticals Inc.
Abstract (Originalsprache)
Plasma lipid levels are modulated by systemic infection and inflammation; it is unknown whether these changes reflect inflammatory responses or caused directly by pathogen presence. We explored the hypothesis that anti-inflammatory intervention via interleukin 6 receptor (IL-6R) blockade would influence plasma lipid levels during severe infection and evaluated the association of plasma lipid changes with clinical outcomes. Sarilumab (monoclonal antibody blocking IL-6R) efficacy was previously assessed in patients with coronavirus disease 2019 (COVID-19) (NCT04315298). This analysis determined whether strong inflammatory reduction by sarilumab in patients with COVID-19 pneumonia of increasing severity (severe, critical, multisystem organ dysfunction) affected plasma lipid changes between day 1 and day 7 of study therapy. Baseline lipid levels reflected the presence of acute systemic infection, characterized by very low HDL-C, low LDL-C, and moderately elevated triglycerides (TGs). Disease severity was associated with progressively more abnormal lipid levels. At day 7, median lipid levels increased more in the sarilumab versus placebo group (HDL-C +10.3%, LDL-C +54.7%, TG +32% vs. HDL-C +1.7%, LDL-C +15.4%, TG +8.8%, respectively). No significant association between lipid changes and clinical outcomes was observed. In conclusion, severe-to-critical COVID-19 pneumonia causes profound HDL-C depression that is only modestly responsive to strong anti-IL-6R inflammatory intervention. Conversely, LDL-C depression is strongly responsive to IL-6R blockade, with LDL-C levels likely returning to the predisease set point. These results advance our understanding of the complex relationship between serum lipids and infection/inflammation and suggest that HDL-C depression during acute contagious disease is driven by infection and not IL-6-mediated inflammation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA.
- Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA. Electronic address: sergio.fazio@regeneron.com.
Förderung
- Regeneron Pharmaceuticals Inc
Zitieren
APA
Mohammadi, K., Sleeman, M. W., Boyapati, A., Bigdelou, P., Geba, G. P., & Fazio, S. (2024). Effect of IL-6R blockade on plasma lipids and clinical outcomes among hospitalized patients with COVID-19 infection. Journal of Lipid Research. https://doi.org/10.1016/j.jlr.2024.100568
Vancouver
Mohammadi K, Sleeman MW, Boyapati A, Bigdelou P, Geba GP, Fazio S. Effect of IL-6R blockade on plasma lipids and clinical outcomes among hospitalized patients with COVID-19 infection. Journal of Lipid Research. 2024. doi:10.1016/j.jlr.2024.100568
BibTeX
@article{Mohammadi2024,
author = {Mohammadi, Kusha and Sleeman, Mark W and Boyapati, Anita and Bigdelou, Parnian and Geba, Gregory P and Fazio, Sergio},
title = {Effect of IL-6R blockade on plasma lipids and clinical outcomes among hospitalized patients with COVID-19 infection},
journal = {Journal of Lipid Research},
year = {2024},
doi = {10.1016/j.jlr.2024.100568}
}
EUVIMED